Pcn68 Advanced Non-Small Cell Lung Cancer in the Private Healthcare System in Brazil: Retrospective Cohort Study

Ferreira, Carlos Gil; Cerqueira, Érica; Alberto, Batista, PharmD, Aheor Student,; Abadi, Márcia Datz; Peixoto, Rodrigo Buzzatti

doi:10.1016/j.vhri.2019.08.133

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ferreira et al. (2019) reported on the journey of NSCLC patients in the private system between 2011 and 2016, finding that most of patients were diagnosed at stage IV, and the average interval between admission and diagnosis was 31 days ( 15 ). Abrao et al.…”

Section: Discussionmentioning

confidence: 99%

“…A study from The Netherlands Cancer Registry found a median time to treatment of 28 days, and a hospital-based registry study conducted in Greece found a median time to treatment of 23 days ( 7 , 17 ). In regard to Brazil, previous analyses reported a median interval of 35 days between diagnosis and the start of treatment in the private sector and roughly 30 days in public healthcare system ( 15 , 16 ). The median interval between diagnosis and treatment was almost two-fold greater for individuals diagnosed before the first medical appointment.…”

Section: Discussionmentioning

confidence: 99%

“…Stratifying according to stage, median time to treatment was 33 and 22 days for those without a prior diagnosis in stages III and IV, respectively, and 64 and 54 for those with a prior diagnosis in stages III and IV, respectively. Most of the studies reports data regardless stage at diagnosis and comparisons could not be performed (7,15,17). Only Abrao et al (2017) described that both patients at stages III and IV had, in majority, a delay in the start of treatment shorter than 1.5 months (16).…”

Section: Discussionmentioning

confidence: 99%

“…Ferreira et al (2019) reported on the journey of NSCLC patients in the private system between 2011 and 2016, finding that most of patients were diagnosed at stage IV, and the average interval between admission and diagnosis was 31 days(15). Abrao et al (2017) published an analysis on the access of lung cancer patients to the Brazilian public healthcare system by reviewing the medical records of individuals followed between July/2008 and December/2014 in São Paulo.…”

mentioning

confidence: 99%

See 3 more Smart Citations

The journey of stage III and IV non-small cell lung cancer patients in the Brazilian private healthcare system: a retrospective study

Cerqueira,

Batista,

Almeida

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is still diagnosed at late stages in Brazil. The availability of newer treatment options has changed patient management, however, few real-world data have been published since then. This is a population-based retrospective cohort study that aims to evaluate the characteristics of stage III/IV NSCLC patients and their journey in the Brazilian private healthcare system. Patients aged ≥18 years, residing in Brazil who had their first medical appointment between 2016 and 2018 were included in the study. The sociodemographic and clinical characteristics of the patients and time intervals of interest were described. A total of 10,394 patients were analyzed. The majority of the patients were male (58.5%) with a median age of 64.0 (IQR = 58.0 – 71.0) years. In relation to characteristics of the disease, most of the tumors were characterized as adenocarcinomas (52.3%) and diagnosed at stage IV (72.2%). Most patients arrived at the hospital with an established NSCLC diagnosis, while 45.7% were diagnosed at the first medical appointment in the hospital or later. For patients who were diagnosed at the first medical appointment or later, a median interval of 15.0 (IQR = 6.0 – 33.0) days was observed between the first medical appointment and the diagnosis. The first treatment was given after a median of 25.0 (IQR = 6.0 – 49.0) days after diagnosis for patients without a prior diagnosis, and 57.0 (IQR: 33.0 – 98.0) days for patients with a prior diagnosis. The most common treatments were chemotherapy alone (33.8%), chemotherapy combined with radiotherapy (21.5%), radiotherapy alone (13.1%), adjuvant or neoadjuvant treatment (9.3%), surgery (3.3%), and immunotherapy (0.7%; alone or combined). At the end of follow-up (September, 2020), 52.3% of the patients had died. Despite having more treatment options in the private sector, data show that there is a need to improve access to technologies.

show abstract

Section: Discussionmentioning

confidence: 99%